Plazomicin: Completed Phase III enrollment

Achaogen completed enrollment of 69 patients into the open-label, international Phase III CARE trial comparing IV plazomicin plus meropenem or tigecycline vs. IV colistin plus meropenem or tigecycline. A separate cohort will evaluate plazomicin plus an antibiotic of investigator’s choice. The company closed enrollment early due to rapid completion of enrollment in its concurrent Phase III EPIC trial to treat complicated urinary tract infections (cUTI). Achaogen plans to submit the CARE data with the NDA, which is based on data from EPIC. ...